A PD Solution to Protect Peritoneal Membranes
PD-protec® by Zytoprotec, which now has FDA orphan drug status, is in Phase III trials among 300 patients in the US and Europe. The product aims to reduce PD complications such as peritonitis and membrane failure.
Read the full article » | Posted 01-11-2018
Related Articles
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
- Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
- Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026